Clinical Study Results
How many participants had serious adverse reactions?
In Part 1, 23.4% of participants who got tremelimumab had serious adverse reactions.
This was 15 out of 64 participants.
• 28.1% of participants with bladder cancer had a serious adverse reaction. This was
9 out of 32 participants.
• 8.3% of participants with triple negative breast cancer had a serious adverse reaction.
This was 1 out of 12 participants.
• 25.0% of participants with pancreatic cancer had a serious adverse reaction. This was
5 out of 20 participants.
The table below shows the serious adverse reactions during Part 1.
Serious adverse reactions in Part 1
Bladder cancer Breast cancer Pancreatic cancer
(out of (out of (out of
32 participants) 12 participants) 20 participants)
Diarrhea 6.3% (2) 0% (0) 10.0% (2)
Inflammation
9.4% (3) 0% (0) 5.0% (1)
of the colon
Vomiting 3.1% (1) 8.3% (1) 0% (0)
Inflammation of
the colon caused
6.3% (2) 0% (0) 0% (0)
by the immune
system
Inflammation of
the liver caused
0% (0) 0% (0) 5.0% (1)
by the immune
system
Inflammation
0% (0) 0% (0) 5.0% (1)
of the lung
Hepatotoxicity,
also known as 3.1% (1) 0% (0) 0% (0)
liver toxicity
Inflammation
of the brain’s 3.1% (1) 0% (0) 0% (0)
pituitary gland
Meningitis 3.1% (1) 0% (0) 0% (0)
7